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Abstract
Background: Omeprazole has recently been described as a modulator of tumour chemoresistance, although its underlying
molecular mechanisms remain controversial. Since pancreatic tumours are highly chemoresistant, a logical step would be to
investigate the pharmacodynamic, morphological and biochemical effects of omeprazole on pancreatic cancer cell lines.
Methodology/Principal Findings: Dose-effect curves of omeprazole, pantoprazole, gemcitabine, 5-fluorouracil and the
combinations of omeprazole and 5-fluorouracil or gemcitabine were generated for the pancreatic cancer cell lines MiaPaCa-
2, ASPC-1, Colo357, PancTu-1, Panc1 and Panc89. They revealed that omeprazole inhibited proliferation at probably non-
toxic concentrations and reversed the hormesis phenomena of 5-fluorouracil. Electron microscopy showed that omeprazole
led to accumulation of phagophores and early autophagosomes in ASPC-1 and MiaPaCa-2 cells. Signal changes indicating
inhibited proliferation and programmed cell death were found by proton NMR spectroscopy of both cell lines when treated
with omeprazole which was identified intracellularly. Omeprazole modulates the lysosomal transport pathway as shown by
Western blot analysis of the expression of LAMP-1, Cathepsin-D and b-COP in lysosome- and Golgi complex containing cell
fractions. Acridine orange staining revealed that the pump function of the vATPase was not specifically inhibited by
omeprazole. Gene expression of the autophagy-related LC3 gene as well as of Bad, Mdr-1, Atg12 and the vATPase was
analysed after treatment of cells with 5-fluorouracil and omeprazole and confirmed the above mentioned results.
Conclusions: We hypothesise that omeprazole interacts with the regulatory functions of the vATPase without inhibiting its
pump function. A modulation of the lysosomal transport pathway and autophagy is caused in pancreatic cancer cells
leading to programmed cell death. This may circumvent common resistance mechanisms of pancreatic cancer. Since
omeprazole use has already been established in clinical practice these results could lead to new clinical applications.
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Introduction
Despite relevant progression in diagnosis, resection and
chemotherapy, pancreatic cancer is associated with a short
survival [1]. Constitutive proliferation and profound resistance to
apoptosis are characteristic features of pancreatic tumour cells
rendering them highly resistant to common chemotherapeutic
strategies. Several mechanisms responsible for apoptosis resistance
have been reported including downregulation of proapoptotic
proteins, upregulation of antiapoptotic proteins [2,3], activation of
various kinases such as protein kinase C (PKC)/ protein kinase D1
(PKD1) and casein kinase 1 (CK1) [4–6], elevated expression of
various microRNAs [7], p53 mutations and mdm2 polymorphisms
[8]. Therefore identification of substances which are able to
circumvent these mechanisms would be valuable.
Recently, omeprazole (OMP), established as a world-wide
standard drug for gastritis and duodenal ulcer since the 1980s, has
been described as a potential antiproliferative agent and a
resistance modulator both in vitro and in xenograft tumours of
mice [9,10]. Further research has suggested that inhibition of the
vacuolar proton pump (vATPase), which regulates the lysosomal
pH, or accumulation within the lysosomes may be the leading
mechanisms for sensitising cells towards cytostatic treatment [9–
12]. In addition, formation of reactive oxygen species [9] and
involvement of p38 MAPK [13] have been reported to be
associated with OMP-induced cellular effects. Furthermore P-
glycoprotein (Pgp) [14] and cytochrome P450 2C19 isoform [15]
cause pharmacokinetic interactions of OMP with other drugs (i.e.
antibiotics, barbiturates, cytostatics) which are of clinical rele-
vance. These data so far point to complex mechanisms involving,
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whether and how OMP may inhibit cancer cell growth and
enhance cytostatic effects of cytostatics are ongoing.
To date, neither the drug itself nor any of its targets have been
directly observed within cancer cells. There is also virtually no
data describing the dose-effect relationship of OMP in tumor cells.
It would be of considerable interest whether this drug is effective in
clinically applicable concentrations. Furthermore, to our knowl-
edge, OMP has not yet been used in pancreatic cancer treatment,
even though data obtained in patients with Zollinger-Ellison-
syndrome show that OMP has a wide therapeutic range and
causes only rare and mild side effects even at higher doses [16]. In
contrast, other resistance modulators such as verapamil [17] or
bafilomycin [18] are too toxic for clinical use.
Considering the high chemoresistance of pancreatic tumour
cells, one of the main aims of our study was to determine whether
OMP would be effective in pancreatic cancer cell lines. Therefore
we investigated the one- and two-dimensional dose-effect rela-
tionships of OMP alone or in combination with 5-fluorouracile (5-
FU) or gemcitabine (GEM) in the well characterized human
pancreatic cancer cell lines MiaPaCa-2, ASPC-1, Colo357, Panc1,
Panc89 and PancTu1 in vitro [19–21]. Our results indicate that
the mean inhibitory concentrations (IC50) of OMP were in the
range of clinical applicability in these cell lines.
For the further investigations we used the two cell lines
MiaPaCa-2 and ASPC-1, and, beside of OMP, the cytostatic 5-
FU in order to evaluate the specificity of the effects OMP causes
within these cell lines.
We investigated the subcellular and molecular changes in
MiaPaCa-2 and ASPC-1 cells treated with OMP. Transmission
electron microscopy (TEM) and proton nuclear magnetic resonance
spectroscopy of viable cells (H-NMRS) were performed. We found
that modulation of autophagy is an early effect of OMP. Moreover,
analysis of subcellular fractions containing lysosomes and Golgi
complexes by Western blot analysis and NMR spectroscopy in
untreated and treated MiaPaCa-2 cells confirmed that lysosomes are
the main intracellular target of OMP leading to effects on protein
recycling and transport pathways, including the Golgi complex.
Our results show that OMP inhibited the growth of pancreatic
cancer cells in a dose-dependent manner and probably at non-
toxic concentrations in vitro. OMP also enhances the effects of 5-
FU and GEM. The lysosomal transport pathway is altered upon
OMP treatment and autophagy is, directly or indirectly,
modulated. Thus, OMP may provide a novel therapeutic
approach in the treatment of pancreatic cancer.
Results
OMP inhibits pancreatic cancer cell proliferation in a dose
dependent manner and enhances the cytostatic effects
of GEM and 5-FU
The dose-effect curves of OMP, pantoprazole (PZL), GEM and
5-FU were generated using the ATP-bioluminescence assay. One
of the aims of our investigations was to evaluate the clinical
applicability of OMP. Therefore we determined the IC50ies by
fitting the curves to a three parameter log-logistic model. The
IC50, listed in table 1, ranged from 9–42 mg/ml for OMP, 22–
99 mg/ml for PZL, 0.004–0.24 mg/ml for GEM and 0.20–
0.57 mg/ml for 5-FU depending on the cell line.
These dose-effect-curves (Figure 1) showed gradual differences of
sigmoidicity and other pharmacodynamic parameters. It is obvious
that in lower concentrations of the drugs the cell count may be even
higher than in the respective control group (values above 1 in
Figure 1) indicating a growth stimulatory effect. This phenomenon,
called hormesis, which is defined as an overcompensatory reponse
of living organisms to various stress factors [22], may account for
resistance development during chemotherapy [23].
Therefore we investigated the effects of OMP when combined
with a cytostatic in lower concentrations in order to evaluate its
role in chemoresistance and hormesis overcome. Additive,
synergistic or antagonistic mutual interactions of two drugs can
be quantified within the quasilinear region of the dose-effect-
curves using the median effect principle of Chou [24] or the
unified response surface area of Greco et al. [25]. However the
interactions of drug combination is difficult to quantify for
hormetic dose-response-relations [26]. There are various models
to assess hormesis for a single drug treatment [27,28].
Table 2 shows the unaffected fraction (fu), which is the cell count
related to control, upon low concentrations of 5-FU and GEM when
used as single agents. In ASPC-1, Panc-1 and PancTu-1 cells
significant elevations of the fu above 1 upon 5-FU, indicating hormesis,
were observed. In contrast there was no significant hormesis upon
GEM. When OMP is added to 5-FU in these concentrations, the
hormesis is mitigated in the ASPC-1, Panc-1 and PancTu-1 cell lines
(Figure 2). In MiaPaCa-2 cells the OMP and 5-FU combination
showed additive effects, in the Panc-89 cell line OMP led to an
antagonistic interaction. In Colo357 cells no dose-effect-curve could be
established due to large standard errors. GEM and OMP showed
additive or antagonistic interactions (data not shown).
Thus, OMP has a dose dependent antiproliferative effect and
the in vitro IC50 of OMP in these support the hypothesis of clinical
applicability (which is discussed further in the discussion section).
However, the dose-effect relationship of the drugs differed between
cell lines. The combined treatment of OMP with either 5-FU or
GEM revealed dose-dependent additive interactions and a
mitigation of the hormetic growth stimulation of low-dose 5-FU
in ASPC-1, Panc1 and Panc89 cells. .
Cell line specific changes in the intralysosomal pH after
treatment of pancreatic cancer cells with OMP and 5-FU
either alone or in combination
Acridine orange (AO) fluorescence microscopy was performed
to determine whether OMP increases the intralysosomal pH as
Table 1. Mean inhibitory concentrations (IC50) of OMP and 5-
FU in various human pancreatic cancer cell lines.
cell line OMP PZL 5-FU Gemcitabine
IC
conf.
int. IC
conf.
int. IC
conf.
int. IC
conf.
int.
MiaPaCa-2 42.4 38–45 68.4 57.8–79.7 0.20 0.12–0.27 0.021 0.013–
0.028
ASPC-1 11.2 7.1–15.4 38.2 12.3–64.1 0.45 0.35–0.55 0.036 0.007–
0.07
Panc-1 31.8 13.4–49.0 22.2 10.7–33.8 0.57 0.38–0.76 0.24 n.n.-
0.57
Colo357 26.4 20.0–32.8 69.7 46.6–92.8 0.48 0.36–0.60 0.0032 0.0008–
0.007
PancTu-1 20.7 5.9–35.4 43.8 25.1–62.5 0.17 0.08–0.26 0.035 n.n.-
0.09
Panc-89 9.1 8.4–9.7 98.8 89.2–108.4 0.20 0.08–0.26 0.005 0.0005–
0.01
The IC50 were determined by ATP-bioluminescence. All values are listed in mg/ml.
Abbreviations: conf. int. - 90% confidence intervals.
doi:10.1371/journal.pone.0020143.t001
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or by accumulating within the lysosomes [11]. Acidic cell
compartments are stained red and neutral compartments are
stained green by AO. Specific inhibition of the vATPase by
bafilomycin A1 has been shown to lead to a rapid inhibition of the
red fluorescence [29,30].
The red-to-green fluorescence ratios quantified by quantitative
image analysis for MiaPaCa-2 and ASPC-1 cells are shown in
Figure 3. The early changes (after 30 minutes of treatment)
consisted of a slightly higher acidity upon 5-FU treatment in
MiaPaCa-2 cells and in ASPC-1 cells treated with OMP or
OMP+5-FU. After 24 hours, the lysosomal acidity of MiaPaCa-2
cells was gradually, but significantly suppressed by OMP, 5-FU
and OMP+5-FU. However these observation do not unequivo-
cally correspond to the above mentioned reports, since the effect
was not specific to OMP. In ASPC-1 cells, all three treatment
regimens resulted in a slightly higher acidity after 24 hours.
Thus we conclude that OMP did not cause a consistent change
in the intralysosomal pH value of pancreatic cancer cells.
Nevertheless a slight inhibition occured in MiaPaCa-2 cells upon
all treatment regimens after 24 hours. In contrast, ASPC-1 cells
showed a higher lysosomal acidity when treated with OMP, 5-FU
or a combination of both.
Phagophores and autophagosomes accumulate in ASPC-
1 and MiaPaCa-2 cells after OMP treatment
So far, our results suggest that vATPase inhibition and lysosomal
pH elevation were not the main effects caused by OMP in
Figure 1. Dose effect curves of omeprazole, 5-fluorouracil, pantoprazole and gemcitabine in various pancreatic cancer cell lines.
ASPC-1, MiaPaCa-2, Colo-357, Panc-1, Panc-89 and PancTu-1 cells were grown in the absence or presence of the indicated concentrations of
omeprazole, 5-fluorouracile, pantoprazole or gemcitabine, respectively, for 4 days to determine the IC50 values. The IC50 ies and the sigmoidicities are
gradually differing between the cell lines. In lower concentrations a slight growth-stimulatory effect (hormesis) was observed.
doi:10.1371/journal.pone.0020143.g001
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copy however revealed that lysosomes were involved in both OMP-
and 5-FU-mediated inhibition of proliferation. Therefore we
examined the subcellular morphological changes after treatment
with OMP, 5-FU and the combination of both by TEM.
Figure 4 compares an untreated ASPC-1 cell (Figure 4 A) with
cells treated with 160 mg/ml (Figure 4B) and with 80 mg/ml OMP
(Figure 4C) for 24 hours. Treatment with 80 mg/ml OMP resulted
in autophagy as indicated by the appearance of early cup-like
phagophores containing cytoplasmic material and autophago-
somes filled with coated vesicles (Figure 4C). After treatment with
160 mg/ml OMP, the ASPC-1 cells underwent apoptosis after 24–
48 hours (figure 4B). Similar changes were observed in MiaPaCa-2
cells treated with 80 mg/ml OMP including vacuolisation as a
concomitant sign of apoptosis (Figure 4D).
Although phagophores were easily identified by unique
morphological characteristics, autophagosomes, lysosomes, endo-
somes and autolysosomes could not be distinguished by TEM.
Significantly higher amounts of all these lysosome-like organells
were observed in ASPC-1 cells treated with OMP or OMP+5-FU
and in MiaPaCa-2 cells treated with OMP+5-FU (Figure 4E).
In summary, OMP led to accumulation of markers of early
stages of autophagy (autophagophores) in both cell lines. Although
markers of later stages, such as autolysosomes, could not be
distinguished morphologically from other lysosomal transport
pathways, the overall number of lysosome-like organelles increased
in ASPC-1 cells upon treatment with OMP or 5-FU+OMP and in
MiaPaCa-2 cells treated with 5-FU+OMP. These findings suggest
that either activation of the protein turnover or impairment of the
lysosomal transport pathway occurred.
Identification of metabolic changes within viable cells
after treatment with OMP, 5-FU or a combination of both
Proton NMR spectroscopy of viable cells was performed in
MiaPaCa-2 and ASPC-1 cell lines in order to analyse the
biochemical processes associated with the morphological changes
described above. Various characteristic low-molecular intracellu-
lar metabolites such as fatty acids, amino acids, membrane
associated phospholipid mebolites and intermediate citrate cycle
and glycolysis metabolites were identified (Figure 5).
OMP itself was detected intracellularly within both cell lines
after treatment with 80 mg/ml for 24 hours. The signals of the
aromatic H8 and H10 protons of OMP (Figure 5C) were easily
identified (Figure 5D) in MiaPaCa-2 cells. OMP was also
identified within ASPC-1 cells by the H5 proton (data not shown).
To our knowledge, this is the first time that OMP has been
observed within cells.
Although the determination of absolute intracellular concen-
trations by NMR spectroscopy is generally prone to systematic
errors, the calculation of integral ratios of various signals may
contain useful quantitative information on the metabolic path-
ways. These metabolic pathways are shown as a strongly simplified
network for ASPC-1 cells in Figure 6 and MiaPaCa-2 cells in
Figure 7. A line between two signals symbolises a metabolic
pathway. The line is orange when the signal intensity ratio of the
connected substances differs from the control with p,0.05 and red
when p is below 0.01.
Membrane-bound fatty acids are usually NMR-visible only
when using the Magic-Angle-Spinning (MAS) technique [31]. In
contrast, mobile polyunsaturated fatty acid (PUFA) groups (viz. the
CH=CH at 5.3 ppm or CH=CHCH2CH=CH at 2.8 ppm),
which have been associated with the formation of lipid drops in
autophagosomes during autophagy and programmed cell death
(PCD) [32], became prominent in the proton NMR spectra of
MiaPaCa-2 cells treated with OMP or 5-FU+OMP. Moreover an
increase in the fatty acid methylene (FACH2) groups compared to
acetate was observed upon OMP and 5-FU+OMP treatment in
MiaPaCa-2-, but not in ASPC-1 cells. This correlates with the
electron microscopy data showing that the morphological changes
associated with autophagy are accompanied by vacuolisation
which points to the beginning of apoptosis in MiaPaCa-2, but not
ASPC-1 cells, at 80 mg/ml OMP.
Cho and Phosphocholine (PC) signals are indicators of growth
in human cells, whereby elevated PC is associated with rapid
proliferation and malignant behaviour [33–35]. The suppression
of PC may be caused by choline kinase and phospholipase C
downregulation and phospholipase A2 induction leading to
proliferation inhibition [36]. In our study, PC was significantly
suppressed compared to Cho in MiaPaCa-2 cells treated with
OMP, 5-FU and 5-FU+OMP and in ASPC-1 cells treated with
OMP alone.
Taken together, these data show that the fatty acid and
phospholipid metabolite signals changed upon OMP treatment.
Although similar changes were observed in both ASPC-1 and
MiaPaCa-2 cells, these changes were more enhanced in MiaPaCa-
2 cells, especially with respect to those signal changes indicating
inhibited proliferation (PC) and PCD (PUFA). This corresponds to
the above described pharmacodynamic and morphologic changes.
However in MiaPaCa-2 cells the biochemical effects were not
limited to OMP treatment, but also occured upon 5-FU and 5-
FU+OMP and thus can not be considered to be specific to OMP.
Involvement of lysosomes and the Golgi complex in the
cellular response to OMP
Potential subcellular targets of OMP were identified by isolating
organelles from MiaPaCa-2 cells by density centrifugation. As
shown in Figure 8, the first and second density fractions contained
early and late endosomes and lysosomes which were identified by
LAMP-1 and Cathepsin-D antibodies (Figure 8B) in the control
Table 2. Detection of growth-stimulatory effects of 5-FU and
GEM in lower doses.
Cell line 5-FU GEM
c( mg/ml) fu p (t-test) c (mg/ml) fu p (t-test)
ASPC-1 0.5 1.4 0.047 0.02 0.5 0.002
1 0.9 0.38 0.04 0.4 0.007
MiaPaCa-2 0.125 0.9 0.4 0.01 0.36 0.01
0.25 0.8 0.2 0.02 0.15 0.003
Colo357 0.5 0.3 0.02 0.02 0.9 0.2
1 0.2 0.01 0.04 0.8 0.06
Panc-1 0.5 1.3 0.02 0.01 0.5 0.0001
1 1.6 0.0003 0.02 0.4 ,0.0001
Panc-89 0.125 0.2 0.01 0.002 0.7 0.02
0.25 0.9 0.3 0.004 0.6 0.04
PancTu-1 0.125 2.2 0.005 0.02 0.35 0.01
0.25 2.2 0.0001 0.04 0.3 0.01
Significant elevations of cell counts compared to the control groups could be
observed upon 5-FU in ASPC-1 (at 0.5 mg/ml 5-FU), Panc-1 (at 0.5 and 1 mg/ml
5-FU) and PancTu-1 (at 0.125 and 0.25 mg/ml) cells. In contrast, no hormesis
could be observed upon GEM.
Abbreviations: c-concentration, fu-unaffected fraction (cell count related to
control).
doi:10.1371/journal.pone.0020143.t002
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in the first fraction. The third fraction of the control group
contained the Golgi complex as indicated by the b-COP antibody.
However, expression of this protein diminished upon OMP
treatment. The proton NMR spectra of these fractions are shown
in figures 8A and 8C. Figure 8A shows the signal assignments
comparing the spectra of these fractions (named F1–F3) to those of
iodixanol (Optiprep), and a lysosomal cell fraction of untreated
cells (F1*), which was washed with PBS once after ultracentrifu-
gation (in contrast to fractions F1–F3, which were washed twice).
Iodixanol occured in all fractions, but decreased after washing the
ultracentrifugates twice. This points to partial incorporation of
iodixanol into the membranes or the lumen of the organelles. Most
of the water-soluble lower-molecular substances decreased also in
F1–F3, such as lactate and citrate, compared to F1*, which
pointed to a washout. The integrity of the organelles were veryfied
by using an external standard (tetrachlorethan) for chemical shift
calibration. There was a pH-dependent shift of the citrate signals
Figure 2. Hormesis of low-dose 5-FU in pancreatic cancer cells and interaction with OMP. The cell lines ASPC-1, MiaPaCa-2, Colo357, Panc-
1, Panc89 and PancTu1 were untreated or treated with 5-FU alone or in combination with the indicated concentrations of OMP for 4 days. At lower
doses of 5-FU alone (black lines, 0 mg/ml OMP) a growth-stimulatory effect (hormesis) was observed in the cell lines ASPC-1, Panc-1 and PancTu-1.
The data points show the means of 8 measurements. The curves are fitted in these cell lines using the Brain-Cousens model (see sub-section 4.11). In
MiaPaCa-2 and Panc-89 cells no hormesis occured, these curves were fitted using a three parameter logistic model. In Colo357 cells the curves could
not be fitted by any pharmacodynamic model due to large standard errors at these lower concentrations (data points shown). The red, green and
blue lines indicate the dose-effect curves of 5-FU when various concentrations of OMP were added (10, 20 and 40 mg/ml, respectively). In ASPC-1 and
Panc-1 cells the hormesis of 5-FU was reversed and in PancTu-1 cell it was mitigated by OMP depending on the concentration of 5-FU. In MiaPaCa-2
cells we found an additive interaction of 5-FU with OMP. In Panc-89 cells the interaction was antagonistic.
doi:10.1371/journal.pone.0020143.g002
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whole cell suspensions.
In contrast to the whole cell spectra (see figure 5B), glyceropho-
sphocholine (GPC) was found in the first (lysosomal) fraction.
When comparing the control to the OMP-treated group
(Figure 8C), the GPC signal clearly diminished upon OMP
treatment. Furthermore, an increase in PUFAs in the OMP-
treated group was confirmed (Figure 8C) analogously to the whole
cell spectra. OMP could not be identified in any of these fractions
and therefore does probably not accumulate in lysosomes or in the
Golgi complex. This underscores the finding that the endosome
and lysosome fractions underwent anabolic changes during OMP
treatment (corresponding to the TEM data). However, the Golgi
complex as a substantial part of the lysosomal transport system, is
also involved.
Determination of autophagic activity
We performed LC3-Western blot analysis to detect changes in
the expression of LC3. The LC3-gene expression correlates well
with the number of autophagosomes [37,38]. Furthermore two
fractions can usually be differentiated - LC3-I and LC3-II. The
first occures in autophagophores and is considered an autophagy
induction indicator, the latter is contained within the autophago-
somes and is degraded, after their fusion with lysosomes, in
autolysosomes. Therefore, by using specific inhibitors of the
autophagic pathway at the level of this fusion, such as Bafilomycin
A1, the induction may be differentiated from the turnover [37,38].
Figure 9 shows the results of the Western blot analysis.
Treatment with Bafilomycin A1 was performed for only 4 hours,
since long-term treatment may lead to cytotoxicity which could
compromise or mask the specific effects of Bafilomycin A1 [37]. In
contrast, OMP and/or 5-FU was added to the medium for
24 hours. Bafilomycin A1 led to a slightly increased LC3-II signal,
while the LC3-I-fraction was not changed. This corresponds to the
already known mechanisms of action [37] and indicates an
Figure 4. Electron microscopy of the ASPC-1 and MiaPaCa-2
cell lines treated or untreated with OMP. (A) ASPC-1 cell without
treatment (800 fold). (B) ASPC-1 cell undergoing apoptosis upon
160 mg/ml OMP after 24 hours (800 fold). Vacuolisation of the
cytoplasma and condensation of the nucleus are visible. (C) Phago-
phores and autophagosomes in a segment of an ASPC-1 cell treated
with omeprazole 80 mg/ml for 24 hours (2800fold enlargement). The
phagophores are characterised by a cup-like shape (white arrows).
Autophagosomes are closed particles, the number of which is increased
in treated cells (black arrows). (D) Early phagophores and autophago-
somes are also found in MiaPaCa-2 cells treated with OMP 80 mg/ml
after 24 hours in a perinuclear region containing lysosomes and the
Golgi complex. In contrast to ASPC-1 cells, early signs of apoptosis such
as vacuolization, are also present. (E) Barchart of the numbers of
autophagosomes and lysosomes per cell in MiaPaCa-2 and ASPC-1 cells
untreated or treated with 5-FU, OMP or the combination of both for
24 hours with standard errors. Significant differences compared to
control are marked by *. In ASPC-1 cells there were significant
differences compared to the control in the OMP group (p: 0.03) and
the 5-FU+OMP group (p: 0.03). In MiaPaCa-2 cells the 5-FU+OMP group
differed significantly from control (p,0.001).
doi:10.1371/journal.pone.0020143.g004
Figure 3. Box-Whisker plots of lysosomal acidity quantified by
AO fluorescence microscopy and image analysis. Acridine
Orange was added to living untreated ASPC-1 and MiaPaCa-2 cells
and cells treated with 5-FU, OMP or the combination of both for
30 minutes or 24 hours. Microscopical life images were taken at 525 nm
(green) and 650 nm (red) to detect changes in the lysosomal pH value
(three images per plate, three plates per group). The red to green
fluorescence ratio of the lysosomes of treated cells were compared to
the control groups by the Mann-Whitney-U-test. Significant differences
compared to control are marked by *. In ASPC-1 cells, after 30 min of
treatment, intralysosomal acidity increased upon treatment with OMP
(p:0.0051) and 5-FU+OMP (p,0.0001). After 24 hours, the acidity is
increased upon all treatment regimens (5-FU - p:0.0002; OMP -
p,0.00001; OMP+5-FU - p:0.037). In MiaPaCa-2 cells the acidity is
elevated after 30 min upon 5-FU (p:0.005) and decreased after
treatment with OMP (p:0.037), 5-FU (p:0.00026) and 5-FU+OMP
(p:0.011) after 24 hours.
doi:10.1371/journal.pone.0020143.g003
Omeprazole Modulates Autophagy in Cancer Cells
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over. In contrast, OMP led to a dose-dependent marked elevation
of both the LC3-I and the LC3-II fractions in MiaPaCa-2 and
ASPC-1 cells which points to both strong autopagy induction and
decreased turnover. Although the LC3-II fraction is seemingly
overproportionally increased compared to the LC3-I fraction, this
ratio was not quantified because of the known artifacts the LC3-I
fraction may undergo [38]. The possible role of autophagy in the
apoptosis induction upon OMP is further addressed in the
Discussion section. 5-FU did not relevantly influence the
autophagic activity and the combination treatment reflects the
effects of OMP. We conclude that OMP induced autophagy in a
dose-dependent manner (indicated by an elevated LC3-II level)
and in the mean time obviously led to an accumulation of the
LC3-II level pointing to impaired autophagosome turnover at the
fusion level. This corresponds to the findings described above.
Comparison of further gene expression patterns in
MiaPaCa-2 and ASPC-1 cells treated with OMP
Although the above described mechanisms may explain some of
the early events that occur after OMP treatment, how they cause
antiproliferative effects still remained unclear. Therefore, we
compared the expression of pro- and antiapoptotic genes as well as
membrane transport protein genes in untreated, OMP- and/or 5-
FU treated cells. The mRNAs of mdr-1, vATPase, mrp, bcl-2, bcl-
xL, bax, bad and survivin genes in ASPC-1 cells were quantified
throughout the first 24 hours of treatment (Figure 10). The pro-
apoptotic bad mRNA was up-regulated by 5-FU (p: 0.038) and 5-
FU+OMP (p: 0.0033) and suppressed by OMP (p: 0.028) in
ASPC-1 cells (after 24 hours). The anti-apoptotic bcl-2 mRNA
was downregulated by 5-FU (p: 0.022), but not by treatment with
OMP or 5-FU+OMP. Hence, we assumed that 5-FU induced
apoptosis rather than autophagy. In contrast, the antiapoptotic
bcl-xL mRNA was significantly downregulated by 5-FU+OMP
(p:0.0017). The mdr-1 mRNA, which codes for the membrane
Pgp and allows the cell to export various toxins, such as OMP, was
significantly upregulated after treatment with OMP for 24 hours
(p: 0.019). However, the mRNA expression of mrp, which is not
known to interact with OMP, did not differ from the control.
Survivin mRNA was significantly downregulated by OMP (p:
0.0059). Survivin promotes cancer progression and survival, and
its suppression is one of the prerequisites of successful cancer
treatment [39]. Cells treated with a combination of 5-FU (5 mg/
ml) and OMP (80 mg/ml) elicited similar responses to cells treated
with 5-FU alone rather than with OMP alone. Upregulation of
mdr-1 and down-regulation of survivin were the most specific gene
expression changes observed upon OMP treatment.
Mdr-1 and vATPase mRNAs were also quantified in MiaPaCa-
2 cells (Figure 11). While the mdr-1 mRNA remained unchanged
in the treatment groups compared to the control group after
24 hours, the vATPase mRNA was significantly upregulated by 5-
FU+OMP.
Western blot analysis revealed that atg12, another specific
marker of autophagy [40,41], was strongly activated upon OMP
treatment in MiaPaCa-2 and ASPC-1 cells and upon 5-FU+OMP
treatment in MiaPaCa-2 cells (Figure 12). Protein expression of
puma, a marker of the BH3-only apoptotic pathway, was up-
regulated in ASPC-1 cells by OMP, but not in MiaPaCa-2 cells
(Figure 12).
Discussion
The enhancement of chemotherapeutic effects as well as
proliferation inhibition and apoptosis induction by OMP have
been described as early as 1999 [10,11,42,43]. To date only one
clinical investigation has reported a potential antitumor effect in
patients. Treatment of gastric MALT-lymphoma by a Helicobac-
ter pylori eradication scheme containing 20 mg OMP once daily
per os resulted in tumour regression [44]. However Katagiri et al
[45] have demonstrated that oral doses of 20 mg OMP led to a
maximal plasma concentration of about 2.5 mg/ml (7 mM) after
two hours in patients. This gastroprotective dose would probably
not be sufficient for an antitumor effect in pancreatic cancer since
our in vitro studies demonstrated that concentrations greater than
30 mg/ml are required to elicit an effect.
Treatment of Zollinger-Ellison-Syndrome with up to 120 mg
OMP three times a day has rare and mild side effects [16] and no
long-term effects [46] (corresponding to a hypothetical in-vivo
peak concentration of about 15 mg/ml). This is in the range of the
IC50 of most cell lines studied here, but overdoses up to 2400 mg
(corresponding to a hypothetical plasma peak concentration of
300 mg/ml) have been tolerated with minor side effects (AstraZe-
neca product information). Thus we hypothesise that if OMP was
to elicit an antitumoral effect in patients, the necessary dose would
possibly be in the tolerable range. While recently published in vivo
data confirmed an antitumoral effect for human melanoma and
colon adenocarcinoma cell lines in SCID mice [10], a phase I
clinical investigation has not yet been performed.
OMP is a prodrug which upon activation blocks gastric parietal
cell proton pumps by disulfid formation in an acid environment
(pH,3). The impact of the medium pH on the antiproliferative
potency of OMP has been recently discussed [13]. Here we used
the ‘‘physiological’’ pH of the medium (7.4), because an acidic
medium may influence the metabolic activity of the tumor cell.
The fact that OMP is also effective when a neutral medium is used
may be explained in two ways: OMP activation within or on
intracellular acid compartments and/or interaction with a
molecular target by the prodrug OMP. An acidic microenviron-
ment of a solid tumour or culture medium acidification through
lactate accumulation may, at least in part, enhance the activation
of OMP and its pharmacodynamic properties.
The IC50ies of those human pancreatic cancer cell lines
described here differ by a factor of approximately four. We
assume that the pharmacodynamic differences shown in Figure 1
Figure 5. Identification of substances from a proton NMR spectrum of viable untreated MiaPaCa-2 cells. The cells were harvested from
monolayer culture, kept and measured at 20uC. Measurement were performed by a 600 MHz Bruker spectrometer. For better visibility the part of the
spectrum showing the protons of aliphatic groups is splitted into 2 parts - A and B. (A). aliphatic part I. The methyl and b- and c- methylene groups of
various fatty acids and amino acids are visible. In addition, isopropanol and tetrachlorethan (the external concentration standard) occured as
pollutions. (B) Aliphatic part II. Phospholipid metabolites and the a-methylene groups of amino acids and lactate are visible. (C) Formula of OMP with
numbering of the respective protons. The methyl groups (1–3, 9) and the methyl group (4) are covered by other metabolites in the aliphatic parts of
the spectrum. In contrast, the aromatic protons are visible (H5, H8, H10). (D) Overlay of the aromatic parts of different spectra for intracellular
identification of OMP. The singulet of the H5 proton and the dublets of the H8 and H10 protons can be identified when the medium and the cell
spectra are compared to those without OMP treatment. Abbreviations: His - histidine, Tyr - tyrosine, Phe – phenylalanine, Leu, Ile, Val - Leucine,
Isoleucine, Valine. Ala - Alanine. Glu - Glutamate, Gln – Glutamine, PC - phosphatidylcholine, Cho - Choline, GPC – glycerophosphocholine, Tau –
taurine, Scyllo - scylloinositole.
doi:10.1371/journal.pone.0020143.g005
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lisation capacities.
OMP has been shown in the past to enhance the antitumoral
effects of cytostatic drugs [10,11]. The pharmacodynamic
interaction assays confirmed that the cytostatic effects of 5-FU
and GEM were also enhanced by OMP in a dose-dependent
manner in the MiaPaCa-2 cell line. The cell lines ASPC-1, Panc-1
and PancTu-1, in contrast, showed a hormetic growth stimulatory
effect of 5-FU, when it is given in doses below the IC50. The
hormesis-phenomenon may contribute to chemoresistance, par-
ticularly when the plasmatic concentration of the drug declines
exponentially after administration or when the tumorous micro-
environment prevents sufficient tissue penetration [22,23]. Never-
theless the molecular basis of this overcompensatory cell response
Figure 6. Simplified metabolic networks of ASPC-1 cells as determined by proton NMR spectroscopy. The ASPC-1 cell line is shown
without and upon various treatment regimens (OMP, 5-FU or 5-FU+OMP combination). The nodes of this network symbolize metabolite signals, their
colours correspond to relative signal intensity (when compared to an external standard) as indicated in the heatmap scale below. The signal intensity
is linearly related to the intracellular concentration. The background of the nodes are left blank when the signal intensity is out of the range indicated
by the heatmap scale. The lines between the boxes symbolize strongly simplified metabolic pathways. The colours of these lines indicate significant
differences of the signal intensity ratios of the connected metabolites compared to the control group when orange (p,0.05), red lines indicate
p,0.01. The most obvious changes is that the PC/Cho ratio is significantly lower in the OMP group compared to the control group. Upon 5-FU, the
Cho/Acetate ratio decrease is the only significant change. In the 5-FU+OMP group, there are several significant changes, i.e.the FACH2/CH=CH ratio
is significantly higher. Moreover, the Cho/Acetate ratio changed upon 5-FU+OMP as in the 5-FU group, but also the citrate/GSH ratio. The cellular
biochemical effects involve mainly the fatty acid and phospholipid metabolism pointing to membrane anabolism. Abbreviations: Gln - glutamine, Ala
- alanine, PC - phosphatidylcholine, Cho – Choline, Lac1+FACH2 - methyl group signal of lactate and methylene groups of the fatty acids, Lac2 -
methylene group of lactate, CH=CH - protons of methin groups of unsaturated fatty acids.
doi:10.1371/journal.pone.0020143.g006
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phenomenon in these three cell lines (Figure 2) and, therefore, may
contribute to chemoresistance overcome in vivo. Panc-89 cells
exhibited a seemingly paradoxical attenuation of the 5-FU
mediated cytotoxicity by OMP, which would be classified as
antagonism in the classical understanding of drug-drug-interac-
tion. Nevertheless in this case there is no hormesis of 5-FU but of
OMP itself, which is reflected in the dose-effect-curves. GEM did
not reveal any hormetic effects, and the combination with OMP
led to sligthly additive interactions (data not shown).
We chose the MiaPaCa-2 and ASPC-1 cell lines for further
studies because of their different pharmacodynamics. The first step
was to verify, whether lysosomal pH was elevated after OMP
treatment [9,11]. AO staining revealed that the lysosomal acidity,
Figure 7. Simplified metabolic network of the MiaPaCa-2 cell line as determined by proton NMR spectroscopy. The cell line is shown
without and upon various treatment regimens (OMP, 5-FU or 5-FU+OMP combination). The nodes of this network symbolize metabolite signals, their
colours correspond to relative signal intensity (when compared to an external standard) as indicated in the heatmap scale below. The signal intensity
is linearly related to the intracellular concentration. The background of the nodes are left blank when the signal intensity is out of the range indicated
by the heatmap scale. The lines between the boxes symbolize strongly simplified metabolic pathways. The colors of these lines indicate significant
differences of the signal intensity ratios of the connected metabolites compared to the control group when orange (p,0.05), red lines indicate
p,0.01. Upon OMP, the PC/Cho ratios are significantly lower compared to control. Furthermore the acetate/FACH2 ratio is significantly decreased in
the OMP group. The latter also showed a higher CH=CH level, the ratio to FACH2 is, however, decreased. Upon 5-FU and 5-FU+OMP, similar changes
could be observed. Furthermore, in contrast to ASPC-1 cells, the Ala/Gln/AMP pathway is also involved. Abbreviations: Gln - glutamine, Ala - alanine,
PC - phosphatidylcholine, Cho - Choline. Lac1+FACH2 - methyl group signal of lactate and methylene groups of the fatty acids, Lac2 - methylene
group of lactate, CH=CH - protons of methin groups of unsaturated fatty acids.
doi:10.1371/journal.pone.0020143.g007
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PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e20143when related to the cytosolic pH, was even increased after
treatment with either OMP or 5-FU+OMP in ASPC-1 cells and
by 5-FU alone in MiaPaCa-2 cells. Only after 24 hours, we
observed a slight, but significant suppression of the lysosomal/
cytosolic acidity ratio in MiaPaCa-2 cells caused by OMP, 5-FU
or a combination of both. The accumulation of acidic lysosomes
within the cell as well as the elevation of the intralysosomal pH
have both been recently described by Luciani et al. [10]. In
addition we found that lysosomal acidification or alkealisation is
not specific to OMP. Moreover OMP is known to be a far less
potent vATPase inhibitor than bafilomycin, a specific vATPase
inhibitor. OMP interacts mainly with cytoplasmic rather than
luminal SH-groups, and then only at concentrations above
100 mM [47]. Accordingly, only a gradual increase in the
lysosomal pH may be observed, if OMP accumulates within the
cell. The fact, that 5-FU has the same effects, rather points to a
regulatory cell function, i.e. stabilisation of cytosolic pH or
decreased lysosomal transport and digestive capacities.
Electron microscopy was performed to further examine the
subcellular morphologic changes. Treatment of ASPC-1 and
MiaPaCa-2 cells with 80 mg/ml led to accumulation of phago-
phores and autophagosomes (Figure 4). When the dose was
increased up to 160 mg/ml, apoptosis developed invariably in
ASPC-1 cells, whereas in MiaPaCa-2 cells, early signs of apoptosis
were already present after treatment with 80 mg/ml. Autophagy is
a constitutive process of normal and transformed cells; but little is
known about the initiation. Various reports suggest that autophagy
may be induced by amino acid starvation [48] or energy depletion
[41]. Autophagy has been associated with PCD following
chemotherapy in apoptosis-resistant cells [49,50]. In contrast,
autophagy has also been described as a survival mechanism for
malignant cells [51,52]. Thus the therapeutic modulation of
autophagy is considered to be a ‘‘double-edged sword’’ [53]. We
hypothesise that the accumulation of the early markers of
autophagy (phagophores and autophagosomes) after treatment
with OMP reflects not only autophagy induction but also a
disturbance of the lysosomal transport system and interferes with
the survival function of autophagy, causing consecutively PCD.
Since our studies have so far shown that OMP treatment affects
the lysosomal transport system and induces autophagy, we decided
to analyse the metabolomics of both cell lines by proton NMR
spectroscopy. OMP itself could be identified, but none of its
known metabolites (i.e. hydroxyomeprazole and omeprazole acid)
[54]. The different transmembrane transport capacities of ASPC-1
and MiaPaCa-2 cells rather than the metabolisation capacities
seem to be responsible for the different pharmacodynamic
characteristics of both cell lines.
The elevation of PUFA and decrease in the PC/Cho ratio after
OMP treatment suggest induction of PCD and may also indicate
catabolism of membranes and proliferation inhibition following
down-regulation of choline kinase [36,55] and upregulation of
phospholipase A2 [34]. Since whole cell NMR spectroscopy
detected a similar treatment response to 5-FU, these data are not
specific to OMP.
To determine where OMP accumulated and how it caused
PCD, we fractionated MiaPaCa-2 cells by ultracentrifugation and
isolated the lysosomes. Proton NMR did not show any
accumulation of OMP within this cell fraction, but Western Blot
analysis which was performed for cell organelle identification
unexpectedly showed that the lysosomes of the control were found
in the first two fractions of the control group but only in the first
(and lightest) fraction of the OMP group. Furthermore b-COP, the
Golgi complex marker, diminished upon OMP treatment. Aniento
et al. [56] reported that ß-COP which aggregates to transport
vesicles of the Golgi complex in a pH dependent manner may be
suppressed by bafilomycin A1 and nigericin thereby impairing the
Figure 8. Analysis of MiaPaCa-2 cell organelles after ultracentrifugation. (A) Overlay of the proton NMR spectrum fragments of the
following suspensions (from top to down): untreated first (lysosomal) cell fraction after ultracentrifgation and one washing (F1*), iodixanole
(Optiprep) suspension, lower (F3), middle (F2) and upper fraction (F1) of the ultracentrifugates after two washings. The chemical shifts of the spectra
were calibrated to the Choline/Phosphatidylcholine (Cho/PC) signal. Apart from iodixanol, we could identify the PUFA groups (methylene groups
situated between two CH=CH groups), Cho/PC and glycerophosphocholine (GPC) in F1* and F1–3. Furthermore we observed lactate and the
methylene groups of fatty acids (at 1.3 ppm), citrate (at 2.55 and 2.7 ppm) and phosphoethanolamine (at 3.1 ppm) in the F1* but not in the F1–F3
groups.. (B) Western blot analysis of LAMP-1, a late endosome marker, which was nearly identically distributed over the first two fractions compared
to Cathepsin-D, in the controle group, but ocurred only in the first fraction in the OMP treated group. b-COP as an indicator of the Golgi-complex, is
found strongly in the lower fraction in the control group, but very weakly in the OMP treated group. Cathepsin - D, an early endosome marker, which
can be found in the upper and middle fraction of the control group, but regarding the OMP group, it was only found in the first one. (E) Overlay of
NMR spectra of all fractions of control and OMP. The most relevant difference is the weaning of the GPC signal after OMP treatment in the 1st fraction
after only 6 hours.
doi:10.1371/journal.pone.0020143.g008
Figure 9. Western Blot analysis with LC3B-antibody in ASPC-1
and MiaPaCa-2 cells. The experiment was repeated three times with
nearly identical results. The LC3-I fractions can be clearly distinguished
above the LC3-II signals. Bafilomycin A1 elevated slightly the LC3-II
signal intensity compared to control in both cell lines. There was a
marked and dose-dependent increase of the signal strength of both
fractions when OMP was used. 5-FU alone did not relevantly influence
the LC3-level. The corresponding b-Actin level is shown below the LC3-
WB to confirm the correctness of this semiquantitative evaluation.
doi:10.1371/journal.pone.0020143.g009
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Our results suggest a similar mechanism in MiaPaCa-2 cells,
although the lysosomal pH was only slightly changed. However
there is evidence that the vATPase functions not only as a proton
pump but also as a pH-sensor [59]. Bafilomycin and Concana-
mycin, which interact with the V-subunit of the vATPase, prevent
the maturing and fusion of lysosomes. This Vsubunit is therefore
believed to take part in the protein sorting function of lysosomes
[60]. We hypothesise that a reversible interaction of OMP with the
vATPase can affect the fusion of the lysosomes with autophago-
somes even without its complete inhibition. This would explain the
results of the Western blot analysis and why OMP is not detectable
by NMR spectroscopy within lysosomes but in the whole cell
spectra.
Furthermore LC3-Western blot analysis was performed in order
to substantiate the specificity of autophagy for OMP and to
discriminate the quantitative changes of autophagy induction from
those of autophagosome turnover. We found that the LC3-II
signal, which indicates the autophagy turnover, was elevated in a
dose dependent manner by OMP, but not 5-FU (Figure 9). The
LC3-I fraction was also induced but the ratio of both was not
quantified because of the known artifacts of LC3-I [37]. We
conclude that OMP induces autophagy and also modulates the
turnover causing accumulation of autophagosomes as described
Figure 10. Gene expression analysis of membranal transport and apoptosis relevant genes in ASPC-1 cells. Quantification of mRNAs in
ASPC-1 cells untreated or treated with OMP 80 mg/ml, 5-FU 5 mg/ml or the combination of both was performed at different time points throughout
24 hours, and the means of three replicates are shown for every time point. The stars indicate significant differences after 24 hours compared to
control. The pro-apoptotic bad-mRNA was upregulated after 5-FU- and 5-FU+OMP-treatment. The antiapoptotic bcl-2 mRNA was downregulated by
5-FU and bcl-XL by 5-FU+OMP. OMP led to downregulation of bad and survivin and to upregulation of the mdr-1 mRNA.
doi:10.1371/journal.pone.0020143.g010
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apoptosis coexist at higher doses (80 and 160 mg/ml) of OMP
raising the question how both processes are interacting. It is now
commonly believed that autophagy itself does not cause apoptosis
but rather serves as an accompanying or frustran survival process
[38]. If this would be the case, OMP should have influenced
apoptosis-controlling genes directly or indirectly.
MRNA quantification revealed the downstream effects including
upregulation of the proapoptotic bad gene and down-regulation of
the anti-apoptotic bcl-2 and bcl-xLgenes24 hours aftertreatmentof
ASPC-1cells with 5-FU and/or5-FU+OMP(Figure10).The mdr-1
gene was up-regulated after OMP treatment indicating another
aspect of the complexity of OMP-mediated effects. The pro-survival
gene survivin was down-regulated by OMP.An association of Pgp
inhibition and survivin down-regulation was also reported by Liu et
al. [61]. In contrast the mdr-1 gene was not upregulated in
MiaPaCa-2 cells. The vATPase was up-regulated 24 hours after
beginning oftreatment with 5-FU+OMP. The Western blot analyses
shown in Figure 12 confirm these observations.
We conclude that OMP inhibited cancer cell proliferation by
interfering with the intrinsic autophagy of ASPC-1 and MiaPaCa-
2 cells via transmembrane transport activation (ASPC-1) as well as
a disrupted lysosomal transport (MiaPaCa-2). Complex biochem-
ical effects caused by OMP as well as 5-FU can be summarised as
changes in phospholipid and membrane metabolism that suggest
the start of PCD. The differences between the cell lines are gradual
and reflect the higher effectivity of OMP in MiaPaCa-2 cells.
Unlike 5-FU, OMP caused no direct involvement of those
apoptosis-controlling pathways investigated here. The coexisting
signs of apoptosis and autophagy activation suggest however that
the autophagy modulation caused by OMP may well be the
starting mechanism or even a part of the PCD itself.
Figure 11. Gene expression analysis of membranal transport and apoptosis relevant genes in MiaPaCa-2 cells. mRNA quantification in
MiaPaCa-2 cells untreated or treated with OMP 80 mg/ml, 5-FU 5 mg/ml or the combination of both was performed at different time points
throughout 24 hours, and the means of three replicates are shown for every time point. While the mdr-1 mRNA is not signicantly changed, the
vATPase mRNA is upregulated in the 5-FU+OMP group after 24 hours compared to control.
doi:10.1371/journal.pone.0020143.g011
Figure 12. Gene expression analysis of autophagy and
apoptosis relevant genes by Western blot analysis. The Bad,
Puma and Atg12 proteins were detected in MiaPaCa-2 and ASPC-1 cells.
The Bad expression is slightly increased by 5-FU and suppressed by
OMP and 5-FU+OMP in ASPC-1, but not in MiaPaCa-2 cells. Puma is
induced by OMP in both cell lines indicating involvement of the BH3-
only pathway. Atg12 is strongly enhanced by OMP in both cell lines.
Abbreviations: K - control, F - 5-FU, O - OMP, FO - 5-FU+OMP.
doi:10.1371/journal.pone.0020143.g012
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overcoming chemotherapy resistance is understood, further
studies, directed at the immediate autophagy induction pathway,
are required.
The clinical relevance of our findings is supported by the fact
that autophagy modulation may circumvent the antiapoptotic
resistance mechanisms characteristic of many tumor entities. Since
OMP has already been established in clinical practice these results
could rapidly lead to the development of new therapeutic strategies
in the treatment of pancreatic cancer.
Materials and Methods
Cell lines
The human pancreatic cancer cell lines MiaPaCa-2 [21],
ASPC-1 [19], Panc1 [62], Colo357 [63], PancTu1 [64], Panc89
(identical to T3M-4) [65] were cultured with RPMI/ DMEM (1:1,
Invitrogen, Karlsruhe, Germany) and were supplemented with
2 mM glutamine, Penicillin/Streptomycin 1% (Invitrogen, Karls-
ruhe, Germany), and 10% FCS (PAA, Co ¨lbe, Germany) at 37uC,
5% CO2.
Drugs
5-FU and OMP (Astra Zeneca, Wedel, Germany) were
obtained from the University’s hospital pharmacy. 5-FU was
dissolved in 0.9% NaCl and stored in the dark at 20uC. OMP was
stored as dry substance at room temperature and dissolved in the
medium directly before use. Medium and drugs were exchanged
daily.
Antibodies
The following primary antibodies were used: Cathepsin D,
Lamp-1 (both obtained from Cell Signalling Inc., Danvers, USA),
b-COP (abcam, Cambridge, UK), Bad (R&D Systems, Minneap-
olis, USA), Puma, Atg12 (both obtained from biomol, Hamburg,
Germany), LC3 (mAB2G6 Enzo Life Sciences, USA), and actin
(mAB, Sigma, USA).
ATP-bioluminescence assays
Determination of the IC50ies: Cells were seeded in 96 well
plates, 1000 viable cells/well, and cultured as described above. In
order to determine the IC50 of 5-FU and OMP, we used 1 control
well and 23 wells with inceasing concentrations of each drug,
which were added 24 h after cell seeding. The ATP content in
each well was determined 4 days later using the HS II ATP-
Bioluminescence Kit (La Roche, Germany). Bioluminescence was
measured with the Lumistar luminometer (BMG Labtech GmbH,
Offenburg, Germany). The IC of each drug was calculated using
the three parameter log-logistic model of the R package ‘‘drc’’
[66,67]. The biphasic (hormetic) dose-effect-curves of the drug
combinations of 5-FU and OMP in various cell lines could not be
fitted using this modell. In these cell lines the Brain-Cousens-
modell with 3 parameters was applied [28].
Acridine Orange (AO) Fluorescence Microscopy
10
4 MiaPaCa-2 and ASPC-1 cells were seeded in 5 cm
2 plates
and incubated for 24 hours. OMP 80 mg/ml , 5-FU 5 mg/ml or
both were then added, and after 30 min or 24 hours of further
incubation, AO (5 mg/ml) was added to the living cells for 15 min.
The medium was then exchanged. Fluorescence analyses were
performed at 525 nm (green) and 650 nm (red) on an Olympus
microscope. Three non-overlapping digital pictures per plate with
a resolution of 137661038 pixels were taken and 3 plates per
group (control, OMP, 5-FU or combination) were grown up. The
brightness value was calibrated to 1–256 for each channel (red,
green, blue).
The CellProfiler software (Broad Institute, Cambridge, UK) was
used for the image processing [68]. Cells and lysosomes were
identified using the ‘‘ExampleSpeckleImages’’ pipeline with some
minor adaptations for both cell lines. The red fluorescence
indicating acid compartments (mainly lysosomes) and the green
fluorescence showing the physiologic pH of the cytosol were
integrated for each cell, and the red-green-ratio was determined.
The integral ratios per cell of the 3 treatment regimens were
compared to control for each time and cell line by the Students t-
test.
Transmission Electron Microscopy (TEM)
2610
3 adherent MiaPaCa-2 or ASPC-1 cells per well,
respectively were seeded on 6 well plates and incubated for
24 hours. After adding 80 mg/ml OMP, 5 mg/ml 5-FU or the
combination of both, cells were incubated for additional 24 hours
before fixation with 2.5% glutaraldehyde (Fluka, Germany)
containing 1.5% saccharose in PBS and post-fixation in 2%
aqueous osmium tetroxide (Fluka, Germany). The samples were
then dehydrated in a 1-propanol series, block stained in 1% uranyl
acetate, and embedded in Epon (Fluka, Germany). Ultra thin
sections of 80 nm were contrasted with 0.3% lead citrate and
imaged in a Philips EM400 TEM. Three wells per cell line and
treatment group were used (overall 24). Ten cells per well were
selected randomly and lysosomes and late autophagosomes were
counted (30 cells per group). Mean numbers were compared by
the Students T-test after confirming normal distribution by the F-
Test.
Nuclear magnetic resonance (NMR) spectroscopy
MiaPaCa-2 and ASPC-1 cells were cultured in 20 cm culture
plates using DMEM without Hepes as medium. Drugs were added
two days after seeding (80 mg/ml OMP, 5 mg/ml 5-FU or both).
Measurements were performed 24 h after adding the drugs. After
washing the cells twice with PBS solution they were harvested from
the plates, centrifuged with 1000 U/min for 5 min, resuspended
in 0.4 ml D2O and transferred into the tubes.Three 5-mm-NMR-
tubes were prepared for each group, each of them containing the
cells of three 20-cm- culture-plates. The cells were kept at 20uC
during preparation and measurement. It was verified that neither
qualitative nor quantitative changes occurred in the spectra, when
the cells were stored at this temperature. Spectroscopy was
performed on a 600 MHz Bruker spectrometer with 128 scans,
3.3 s repetition time and water suppression. The spectra were
analyzed and the signals integrated with Win-NMR 1D software
(Bruker, Karlsruhe, Germany). The Fourier transformation was
performed without LP filling and apodization. Signal identification
was based on peak spiking and literature. We used the methyl
doublet of lactate as a chemical shift reference at 1.3 ppm.
The statistical calculation and the network creation was done
using the R package ‘‘Rgraphviz’’ [67,69].
Lysosome enrichment by ultracentrifugation of MiaPaCa-
2 cells
MiaPaCa-2 cells were cultured in DMEM without Hepes. After
two days OMP 80 mg/ml was added to the medium for additional
24 hours in the treated group. Cells were lysed by douncing. The
Lysosome enrichment kit (Pierce, Rockford, USA) was used for
lysosomal purification following the instructions of the manufactor
as described elsewhere before [70]. About 10 cells were used for
each of the two groups: control and OMP 80 mg/ml six hours after
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30 min at 18000 G. The ultracentrifugates were washed twice
before NMR spectroscopy according to the instructions of the
manufacturer. NMR spectroscopy was performed as described in
subsection ‘‘Nuclear magnetic resonance (NMR) spectroscopy’’.
Western blot analysis
MiaPaCa-2 and ASPC-1 cells were incubated 24 hours either
untreated or treated with bafilomycin A1 (1 mM) for two hours, or
with various concentrations of OMP (40, 80, 160 mg/ml), 5-FU
(5 mg/ml) or the combination of OMP 80 mg/ml and 5-FU 5 mg/
ml for 24 hours.
Cells extracts were clarified by centrifugation at 15000 g for
20 min at 4uC and the protein concentration of the lysates was
determined using the BCA (bicinchoninic acid) protein assay
(Pierce, Rockford, USA). In each case, equal protein amounts, or
equal volumes of single fractions derived from lysosome enrich-
ment of control and OMP treated cells (see subsection 4.8) were
loaded on 12.5% SDS/-gels and transferred onto a Hybond C
super nitrocellulose blotting membrane (GE Healthcare). The
membranes were blocked in TBS containing 0.1% (v/v) Tween 20
and 5% (w/v) non-fat milk for 1 h before being probed with
primary rabbit polyclonal antibodies either specific for Bad
(1:1000 dilution, R&D, USA, 1:600), PUMA (Epitomics, CA,
USA, 1:1000 dilution), Atg12 (Biomol, Hamburg, Germany, 1:200
dilution), LAMP-1 (1:500 dilution, b-COP (1:1000), Cathepsin D
(1:1000 dilution), LC3 (0.5 mg/ml) or actin (Sigma, 1:10000
dilution) . Immuncomplexes were detected by incubation for
45 min with the appropriate HRP-conjugated secondary antibody
(1:1000 dilution), followed by ECL (enhanced chemiluminescence)
detection (GE Healthcare). Each of these investigation was
repeated three times.
mRNA quantification
The cells were seeded on 10 cm
2 culture plates and incubated as
described above for 24 hours. Drugs were added as described
above. Three plates per cell line, time point and treatment group
were used. After 0 (control), 6, 12, 18 and 24 hours, the cells were
trypsinized, kept on ice and washed twice with PBS. Thereafter,
they were kept at 280uC till mRNA extraction. Bad, bax, bcl-2,
bcl-xl, v-ATPase, mdr-1, mrp, survivin and gapdh transcripts were
measured from cDNA in duplicate experiments using ready-to-use
PCR testkits (Roboscreen Gesellschaft fu ¨r molekulare Biotechno-
logie, Leipzig, Germany) [62].
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